Donor tolerability of convalescent plasma donation

He, Rui; Lin, Hui; Xie, Songli; Lv, Qilu; Kong, Yujie; Li, Ling; Xu, Haixia; Wang, Jue; Li, Wenjuan; Fang, Peng; Wu, Yanyun; Liu, Zhong

BACKGROUND: Since early 2020, convalescent plasma has been widely used for treating coronavirus disease 2019 (COVID‐19). There is limited information regarding donor tolerability of convalescent plasma donation. In this study, we evaluated the short‐term donor tolerability of convalescent plasma donation. METHODS: A prospective study of 309 convalescent plasma donation related adverse events were conducted at Wuhan Blood Center of China, from February 12 to April 1, 2020. Additionally, up to 28‐day post‐donation follow‐ups were performed on the donors. RESULTS: Sixteen (5.2%) adverse events were reported in 309 donations. All of these were mild vasovagal without loss of consciousness. The frequency of adverse reactions was higher in donors with a per donation volume of >8 mL/kg body weight or ≥ 600 mL, <100 mm Hg in pre‐donation systolic blood pressure, or less than 28 days from the onset of COVID‐19 symptoms. There was no correlation to donation history, weight, sex, ABO blood type, pre‐donation diastolic blood pressure, pulse, or hemoglobin. CONCLUSION: The donation of convalescent plasma is generally safe. Mitigation of risk factors associated with adverse events can further enhance donor tolerability of convalescent plasma donation.